A new study with more than 1700 patients finds that
the drug donanemab slows down the cognitive decline due to
Alzheimer's disease by about a third. While it is not a cure, it
can give patients many quality years of life.
Contact: info@neat-news.com.
neat-news.com is not responsible for the content of external sites.
We do not link to external sites in return for money or any other benefits.
The page is maintained in Germany and for any legal matters the laws of Germany apply.
Any warranty or liability is excluded in the widest legally possible sense.